Daniele Piomelli Selected Research

URB937

1/2021	Characterization of the peripheral FAAH inhibitor, URB937, in animal models of acute and chronic migraine.
1/2020	FAAH inhibition as a preventive treatment for migraine: A pre-clinical study.
12/2019	Pharmacokinetics, pharmacodynamics and safety studies on URB937, a peripherally restricted fatty acid amide hydrolase inhibitor, in rats.
11/2017	Suppression of acute and anticipatory nausea by peripherally restricted fatty acid amide hydrolase inhibitor in animal models: role of PPARα and CB1 receptors.
5/2012	Peripheral FAAH inhibition causes profound antinociception and protects against indomethacin-induced gastric lesions.
10/2011	The ABC membrane transporter ABCG2 prevents access of FAAH inhibitor URB937 to the central nervous system.
10/2010	Anandamide suppresses pain initiation through a peripheral endocannabinoid mechanism.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Daniele Piomelli Research Topics

Disease

63	Pain (Aches) 07/2022 - 01/2004
46	Inflammation (Inflammations) 07/2022 - 01/2005
14	Hyperalgesia 07/2022 - 02/2006
14	Obesity 01/2022 - 07/2004
14	Body Weight (Weight, Body) 01/2021 - 09/2003
11	Neoplasms (Cancer) 11/2021 - 01/2012
10	Alzheimer Disease (Alzheimer's Disease) 01/2019 - 01/2010
7	Migraine Disorders (Migraine) 07/2022 - 12/2015
6	Chronic Pain 10/2021 - 02/2006
6	Substance-Related Disorders (Drug Abuse) 09/2017 - 01/2004
5	Melanoma (Melanoma, Malignant) 10/2021 - 01/2016
5	Wounds and Injuries (Trauma) 12/2020 - 10/2014
5	Neuralgia (Stump Neuralgia) 10/2017 - 02/2006
5	Cognitive Dysfunction 01/2013 - 01/2010
4	Nausea 11/2021 - 02/2007
4	Neurodegenerative Diseases (Neurodegenerative Disease) 01/2021 - 03/2014
4	Hypersensitivity (Allergy) 01/2021 - 04/2009
4	Schizophrenia (Dementia Praecox) 01/2019 - 11/2004
3	Multiple Sclerosis 01/2021 - 01/2016
3	Parkinson Disease (Parkinson's Disease) 01/2021 - 09/2003
3	Chronic Kidney Failure (Chronic Renal Failure) 01/2021 - 10/2019
3	Mood Disorders (Mood Disorder) 01/2020 - 11/2004
3	Breast Neoplasms (Breast Cancer) 01/2020 - 10/2011
3	Ischemia 01/2020 - 08/2002
3	Psychotic Disorders (Schizoaffective Disorder) 01/2019 - 08/2007
3	Edema (Dropsy) 01/2018 - 01/2005
3	Alcoholism (Alcohol Abuse) 01/2016 - 07/2007
3	Marijuana Abuse (Cannabis Abuse) 01/2009 - 12/2002
2	COVID-19 01/2022 - 12/2020
2	Peripheral Nervous System Diseases (PNS Diseases) 11/2021 - 09/2005
2	Vomiting 11/2021 - 02/2007
2	Muscular Diseases (Myopathy) 01/2021 - 03/2014
2	Cachexia 01/2021 - 01/2020
2	Osteitis Deformans (Paget's Disease of Bone) 01/2021 - 03/2014
2	Amyotrophic Lateral Sclerosis (Lou Gehrig's Disease) 01/2021 - 03/2014
2	Frontotemporal Dementia (Semantic Dementia) 01/2021 - 03/2014
2	Post-Traumatic Stress Disorders (Post Traumatic Stress Disorder) 01/2020 - 11/2018

Drug/Important Bio-Agent (IBA)

37	EndocannabinoidsIBA 07/2022 - 08/2003
36	LipidsIBA 07/2022 - 09/2003
29	anandamide (arachidonylethanolamide)IBA 01/2021 - 08/2002
21	CannabinoidsIBA 11/2021 - 11/2002
20	palmidrolIBA 01/2022 - 08/2002
16	oleoylethanolamideIBA 01/2022 - 11/2002
15	fatty-acid amide hydrolase (fatty acid amide hydrolase)IBA 07/2022 - 09/2005
13	PPAR alphaIBA 11/2016 - 09/2003
12	Peroxisome Proliferator-Activated Receptors (PPAR)IBA 01/2022 - 07/2008
12	Cannabinoid Receptors (Cannabinoid Receptor)IBA 01/2021 - 12/2002
11	cyclohexyl carbamic acid 3'-carbamoylbiphenyl-3-yl ester (URB597)IBA 07/2022 - 02/2006
11	amidaseIBA 01/2022 - 12/2009
11	CeramidesIBA 03/2021 - 01/2013
11	Pharmaceutical PreparationsIBA 01/2021 - 09/2003
10	N-acylethanolaminesIBA 01/2022 - 12/2009
10	AcidsIBA 01/2022 - 07/2007
10	EnzymesIBA 10/2021 - 01/2011
10	Fatty Acids (Saturated Fatty Acids)IBA 03/2021 - 08/2002
8	AmidesIBA 07/2022 - 08/2002
8	Formaldehyde (Formol)FDA Link 12/2021 - 12/2006
8	Proteins (Proteins, Gene)FDA Link 01/2021 - 11/2009
8	CarrageenanIBA 01/2021 - 01/2005
8	Analgesics (Analgesic Drugs)IBA 01/2018 - 02/2006
7	URB937IBA 01/2021 - 10/2010
7	Cytoplasmic and Nuclear Receptors (Nuclear Receptors)IBA 11/2010 - 09/2003
6	Acid CeramidaseIBA 10/2021 - 01/2013
6	CB1 Cannabinoid Receptor (CB1 Receptor)IBA 01/2021 - 09/2003
5	HydrolasesIBA 01/2022 - 02/2013
5	glyceryl 2-arachidonate (2-arachidonoylglycerol)IBA 01/2018 - 09/2003
5	Monoacylglycerol LipasesIBA 01/2018 - 08/2011
5	Cannabinoid Receptor AgonistsIBA 10/2008 - 09/2003
4	Nitroglycerin (Dynamite)FDA LinkGeneric 07/2022 - 01/2018
4	Cysteine (L-Cysteine)FDA Link 01/2022 - 01/2013
4	5-phenylpentyl N- ((2S,3R)- 2- methyl- 4- oxo- oxetan- 3- yl)carbamateIBA 01/2018 - 09/2012
4	GW 7647IBA 11/2017 - 12/2006
3	Peptides (Polypeptides)IBA 07/2022 - 08/2012
3	CytokinesIBA 07/2022 - 07/2008
3	Therapeutic UsesIBA 12/2021 - 06/2015
3	Doxorubicin (Adriamycin)FDA LinkGeneric 10/2021 - 02/2006
3	SphingolipidsIBA 03/2021 - 01/2015
3	1-dodecylpyridoxal (PLD)IBA 01/2021 - 03/2015
3	Biomarkers (Surrogate Marker)IBA 01/2021 - 01/2014
3	Serine (L-Serine)FDA Link 01/2020 - 02/2013
3	JZL 184IBA 01/2020 - 08/2011
3	URB602IBA 01/2018 - 08/2011
3	Opioid Analgesics (Opioids)IBA 01/2016 - 06/2005
3	Memantine (Namenda)FDA Link 03/2013 - 01/2012
3	Ethanolamine (Colamine)IBA 07/2008 - 01/2005
3	Palmitic Acid (Hexadecanoic Acid)IBA 07/2008 - 01/2005
3	OleylethanolamideIBA 02/2006 - 08/2002
2	Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)IBA 07/2022 - 01/2014
2	CarbamatesIBA 07/2022 - 09/2009
2	CholesterolIBA 01/2022 - 01/2010
2	AM 251 (AM251)IBA 01/2021 - 06/2015
2	Valosin Containing ProteinIBA 01/2021 - 03/2014
2	iodopravadoline (AM 630)IBA 01/2021 - 05/2010
2	Transcription Factors (Transcription Factor)IBA 01/2021 - 07/2008

Therapy/Procedure

17	Therapeutics 10/2021 - 09/2003
4	Oral Administration 01/2021 - 07/2007
4	Ligation 01/2021 - 02/2006
3	Drug Therapy (Chemotherapy) 11/2021 - 02/2008
3	Topical Administration 09/2015 - 03/2013
2	Renal Dialysis (Hemodialysis) 01/2021 - 01/2020